The Celsion Corporation (CLSN) Shares Gap Down to $0.00

The Celsion Corporation (CLSN) Shares Gap Down to $0.00

Shares of Celsion Corporation (NASDAQ:CLSN) gapped down prior to trading on Friday . The stock had previously closed at ($5.40), but opened at $0.00. Celsion Corporation shares last traded at $0.00, with a volume of 10781574 shares traded.

A number of analysts have recently issued reports on the stock. Maxim Group raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Wednesday, October 4th. ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Tuesday, August 29th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $12.63.

An institutional investor recently raised its position in Celsion Corporation stock. Renaissance Technologies LLC increased its holdings in shares of Celsion Corporation (NASDAQ:CLSN) by 100.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,375,147 shares of the biotechnology company’s stock after purchasing an additional 690,349 shares during the period. Renaissance Technologies LLC owned approximately 2.48% of Celsion Corporation worth $397,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.47% of the company’s stock.

Celsion Corporation Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Related posts

Leave a Comment